Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 192, 113650
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma AG
- iNOVA4Health (UIDB/Multi/04462/2020)
- Fundação para a Ciência e Tecnologia / Ministério da Educação e Ciência
This publication has 30 references indexed in Scilit:
- A generic workflow for the characterization of therapeutic monoclonal antibodies—application to daratumumabAnalytical and Bioanalytical Chemistry, 2019
- Structure, heterogeneity and developability assessment of therapeutic antibodiesmAbs, 2018
- Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodiesJournal of Chromatography B, 2017
- Protocols for the analytical characterization of therapeutic monoclonal antibodies. I – Non-denaturing chromatographic techniquesJournal of Chromatography B, 2017
- Dynamic light scattering: a practical guide and applications in biomedical sciencesBiophysical Reviews, 2016
- Concentration-dependent changes in apparent diffusion coefficients as indicator for colloidal stability of protein solutionsInternational Journal of Pharmaceutics, 2016
- Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies2016
- Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In VitroPLOS ONE, 2014
- Applications of imaged capillary isoelectric focussing technique in development of biopharmaceutical glycoprotein‐based productsElectrophoresis, 2012
- Biotechnology applications of amino acids in protein purification and formulationsAmino Acids, 2007